Symbol="EIGR"
AssetType="Common Stock"
Name="Eiger Biopharmaceuticals Inc"
Description="Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. The company is headquartered in Palo Alto, California."
CIK="1305253"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2155 PARK BOULEVARD, PALO ALTO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="34108200"
EBITDA="-92798000"
PERatio="None"
PEGRatio="0"
BookValue="0.345"
DividendPerShare="0"
DividendYield="0"
EPS="-1.93"
RevenuePerShareTTM="0.351"
ProfitMargin="0"
OperatingMarginTTM="-6.01"
ReturnOnAssetsTTM="-0.493"
ReturnOnEquityTTM="-1.619"
RevenueTTM="15481000"
GrossProfitTTM="11647000"
DilutedEPSTTM="-1.93"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.135"
AnalystTargetPrice="3.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.551"
PriceToBookRatio="0.76"
EVToRevenue="8.36"
EVToEBITDA="0.247"
Beta="1.714"
num_52WeekHigh="9.08"
num_52WeekLow="0.527"
num_50DayMovingAverage="0.767"
num_200DayMovingAverage="1.577"
SharesOutstanding="44296400"
DividendDate="None"
ExDividendDate="None"
symbol="EIGR"
open="0.68"
high="0.81"
low="0.67"
price="0.77"
volume="326534.00"
latest_trading_day="2023-08-18"
previous_close="0.70"
change="0.07"
change_percent="10.0000%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="86"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="14"
Volume_recent_avg="409603"
Change_recent_avg="-0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.77"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="14"
Aroon_momentum_negative="86"
image_negative_thumbnail_id_1="1088"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0121.jpeg"
image_negative_thumbnail_id_2="518"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0087.jpeg"
image_neutral_thumbnail_id_1="563"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_neutral_thumbnail_id_2="529"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0070.jpeg"
image_positive_thumbnail_id_1="981"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0143.jpeg"
image_positive_thumbnail_id_2="672"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0036.jpeg"
image_professor_thumbnail_id_1="1171"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
image_professor_thumbnail_id_2="1187"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
